Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no changes to core study details or user-facing information are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedDeleted the funding-lapse warning block that warned users information may not be up to date due to government funding gaps; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedThe two screenshots show only minor layout adjustments and wording changes on the study page, with no edits to core study data such as eligibility criteria, endpoints, locations, or protocol. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check70 days agoChange DetectedSummary of changes: added a government-operating-status notice and new version v3.2.0; removed the older disease entry (B-cell chronic lymphocytic leukemia) and old version v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedPage updated from Revision v3.0.1 to v3.0.2; the 'Back to Top' link was removed. No substantive changes to core content are evident.SummaryDifference0.2%

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.